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INTRODUCTION
Asiatic acid is an active principle inCentella asiatica
Linn., a medicinal plant. C. asiatica has been shown
to inhibit the proliferation of transformed cell lines
and to retard the development of solid and ascites
tumors (1). We have reported that C. asiatica extract
inhibited the formation of azoxymethane (AOM)-
induced aberrant crypt foci (ACF) and AOM-induced
tumorigenesis in the rat colon (2). Asiatic acid has
a common structure of pentacyclic triterpenes and
belongs to the amyrin ursolic acid group. Ursolic acid
is widely distributed in medicinal herbs and edible
plants (3, 4) and has been shown to exhibit growth in-
hibition properties against many human cancer cell
lines (5 -8). Lee et al. (9) reported that asiatic acid in-
duces apoptosis in HepG2 human hepatoma cells.
However, its activity for inducing apoptosis in vari-
ous cancer cell lines has not been examined.
Apoptosis has recently become a subject of much
interest in cancer chemotherapy. Bcl-2 family proteins
are involved in the regulation of apoptosis either as
death antagonists or death agonists (10 -12). These
antiapoptotic proteins act at upstream processes of
activation of apoptotic proteases such as caspase-3 by
preventing apoptotic signaling in cells (12, 13). While
many tumor cells overexpress antiapoptotic proteins
Bcl-2 and Bcl-xL to become resistant to chemotherapy
and radiotherapy (14, 15), some triterpenes have been
reported to affect the level of expressionofbcl-2 (16, 17).
Irinotecan hydrochloride (CPT-11), a water-soluble
derivative of camptothecin (18), presents a wide spec-
trum of antitumor activity through inhibition of DNA
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topoisomerase I. CPT-11 prevents DNA-religation re-
action, resulting in DNA doublestrand breaks and
eventually leading to apoptosis (19). It has shown cy-
totoxic activity in several malignant tumors, including
cervical, breast, lung, ovarian, pancreatic, renal, colon
and oesophageal cancers, leukemia and lymphoma
(20 -30). However, leukopenia and diarrhea are two
major side effects in patients receiving CPT-11, often
accompanied by cramping, flushing, and sweating.
Grade 3-4 leukopenia and diarrheawere noted in sev-
eral studies (26, 27, 31). Weekly chemotherapy regi-
mens incorporating multiple drugs into one regimen
have been developped to obtain the maximum anti-
tumor effect with reduced adverse effects of the drugs
(32). Recently, the antitumor effect of combinational
therapy using an anticancer drug and a phytochemi-
cal has been studied (33-35). We previously reported
that betulinic acid, a pentacyclic triterpene isolated
from medicinal plants, augments the cytotoxic effect
of vincristine on B16F10 melanoma cells (36). Since
asiatic acid has been reported to induce apoptosis in
hepatoma cells (9) and has a common structure of
triterpenic acid, we expected that combinational treat-
ment with CPT-11 and asiatic acid would show additive
or synergistic cytotoxicity for human colon tumor cells.
In this study, we found that asiatic acid inducedapop-
totic cell death via caspase-3 activation. Furthermore,
we evaluated the effectiveness of combinational treat-
ment with CPT-11 and asiatic acid for HT-29 human
colon cancer cells by isobologram analysis (37, 38).
MATERIALS AND METHODS
Chemicals
Asiatic acid (Fig.1A) was purchased fromFunakoshi
Co., Ltd. Tokyo, Japan. CPT-11(irinotecan hydrochlo-
ride trihydrate) was purchased fromTorontoResearch
Chemicals Inc., North York, ON, Canada. Other re-
agents were reagent gradeorhigher andobtained from
Wako Pure Chemical Industries (Osaka, Japan).
Cell lines and culture conditions
Cells of the human colonic adenocarcinoma cell line
HT-29(American Type Culture Collection, Rockville,
USA) were grown at 37℃ in a fully humidified atmos-
phere containing 5% CO2. HT-29 cells were cultured in
McCoy’s 5Amedium (ICNBiomedical,Ohio,USA) sup-
plemented with 10% heat-inactivated fetal bovine serum
(FBS, GIBCO-BRL, Grand Island, NY), 100 units/ml
penicillin, and 100 µg/ml streptomycin sulfate. The
number of viable cells was determined using a hemo-
cytometer based upon their exclusion of 0.2% trypan
blue dye.
Cytotoxicity
Cells were plated at 1×104 cells/well in 96-well culture
plates, cultured for 24 h, and then treated with asiatic
acid and/or CPT-11. Asiatic acid at final concentrations
ranging from10 to60µg/ml and CPT-11, from10 to
200 µM, were added to the cultures in triplicate in a
final volume of 100 µl. For combination studies, three
different schedules of exposurewere tested:asiatic acid
and CPT-11 simultaneously for 24 h, CPT-11 for 24hand
then asiatic acid for 24 h, and asiatic acid for 24 h and
then CPT-11 for 24 h. After drug exposure, themedia in
the control and drug-containing wells were removed
and 100 µl of fresh media were added. Then 20 µl of
3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2 H-tetrazolium, inner salt (MTS)
(Promega, Corp., Madison, WI, USA) solution was
added to each well according to the manufacturer’s
Fig 1．(A) Structure of asiatic acid (2, 3, 23-trihydroxyurs-12-en-
28-oic acid). (B) Cytotoxicity of asiatic acid for HT-29 cells. Cells
(1×104 cells/well) were exposed to various concentrations of asiatic
acid for 24 h. Viable cell numbers were determined by using the
MTS assay as described in MATERIALS ANDMETHODS. Each
value is % of viable cell number of the solvent control and expressed
as the mean ± SD calculated from 3 wells.
P. Bunpo et al. Effect of asiatic acid and CPT-11 on HT-29 cells６６
instructions. The solutionswere incubated for a certain
time, and the absorbance was then measured at 490
and 630 nm. The results are calculated as follows : rela-
tive viability (%)=[(experimental absorbance－back-
ground absorbance)÷(absorbance of untreated controls
－background absorbance)]×100.
DNA fragmentation analysis
DNA fragmentation in cells treatedwith asiatic acid
was analyzed by the procedure ofOhyama (39). Briefly,
1×106 cells were lysed in 100 µl of chilled lysis buffer
containing 10 mM Tris-HCl (pH7.4), 150 mMNaCl,
2.5 mM EDTA, and 1%Triton X-100. The samples were
held on ice for 15min, and then 2 µl of RNase A (1mg/
ml, Wako Pure Chemical Industries, Ltd., Osaka, Japan)
and 2 µl of RNase T1 (3,340units/ml,Wako)were added
and the mixtures were incubated at 37℃ for 1h. The
lysed cells were treatedwith 2 µl of proteinaseK (Wako)
at 50℃ for 30min. DNAwas precipitatedwith isopropyl
alcohol and dried by a speed vacuum concentrator
(Tomy Seiko, Tokyo, Japan). The pellet was dissolved in
Tris-EDTA buffer (pH 7.4).DNA(2-5µg/lane)waselec-
trophoresed in 2% agarose gel using Tris-borate EDTA
buffer (pH 7.4) with a voltage of 100 V for 45min, and
DNA bands were stained with 0.5 µg/ml ethidium
bromide and visualized under a UV transilluminator.
If necessary, a caspase-3 inhibitor, Z-Asp-Glu-Val-Asp-
FMK (Z : benzyloxycarbonyl, FMK : fluoromethylke-
tone ; MBLMedical &Biological Laboratories Co., Ltd,
Nagoya, Japan), was added at a concentration of 0.1-
30 µM.
Assessment of cell death using flow cytometry
Cells(1×106) were seeded onto 6-well plates. After
treatment with asiatic acid, cells were harvested and
resuspended in 100 µl of a reactionmixture containing
annexin V-FITC and propidium iodide (PI) according
to the instructions of themanufacturer (R&DSystems,
Minneapolis, MN). Cells binding annexinVbut exclud-
ing PI were judged to be early apoptotic cells,whereas
cells binding annexinVandaccumulatingPIwere judged
to be late apoptotic cells. In all experiments, fluores-
cence was determined from the combined collection
of floating and attached cells by a flow cytometer (Coul-
ter Epics XL-MCL, Beckman Coulter, Tokyo, Japan).
Western blot analysis
Whole cell lysateswerepreparedasdescribedpreviously
(40). Briefly, cells were harvested by centrifugation
at 1,000 g for 5min at 4℃. The cell pellets (3×106 cells)
were washed once with ice-cold PBS and resuspended
with 100 µl of the chilled lysis buffer containing 20 µg/
ml leupeptin, 20 µg/ml aprotinin and 0.2 mM phenyl-
methylsulfonylfluoride (PMSF). Cells were disrupted
by passing 10 times throughaG27needle.After sequen-
tial centrifugation at 750 g for 5 min and at 15,000 g for
15 min at 4℃, the supernatants were divided into
aliquots and stored at －20℃. Protein concentration
was determined using a Coomassie protein assay kit
(Pierce, Rockford, USA) according to the manufac-
turer’s instructions. Samples were subjected to 12%
SDS-polyacrylamide gel (Wako) electrophoresis with
200 V for 35 min and transferred to polyvinylidene
difluoride (PVDF) membranes (Bio-Rad, Hercules,
CA, USA) with 20 V for 40min. Themembranes were
blocked in TTBS (Tween 20-Tris-buffered saline) con-
taining 2% bovine serum albumin (BSA) for 1 h and
probed overnight with a primary antibody mouse anti-
Bcl-2 andmouse anti-Bcl-xL[1 : 1,000 ; BDTransduction,
Japan] or with mouse anti-β-actin [1 : 10,000 ; Sigma
Chemical Co., St. Louis, MO]) at 4℃. Primary anti-
body binding was detected with a goat anti-mouse IgG
conjugated with alkaline phosphatase (1 : 2,000 ; Sigma)
and visualized by an enhanced chemiluminescence
method using disodium3-(4-methoxyspiro {1,2-dioxetane,
3,2’ -(5’ -chloro) tricyclo[3.3.1.13,7] decan}-4-yl)phenyl
phosphate (CSPD)(Boehringer, Manheim Germany).
Assay of caspase-3 activity
The activity of caspase-3 inHT-29 cells wasmeasured
using apopain substrate (Sigma) according to the user’s
manual (BDBiosciences ClontechCo., Palo Alto, CA).
Cells(1×106) were plated for 24 h and exposed to asi-
atic acid for a further 12 h. Cells were collected by cen-
trifugation, resuspended in 50 µl of the chilled lysis
buffer as described above, and held on ice for 15 min.
Fifty µl of the reaction buffer containing 1 µl of 1 M
DTT and 5 µl of 1 mM acetyl-Asp-Glu-Val-Asp-7-amido-
4-methylcoumarin (Ac-DEVD-AMC) was added to the
cell lysate, and the mixture was incubated at 37℃
for 1h. The fluorescence emitted at 450 nm (λex=365
nm) was measured with a microplate reader spec-
trofluorometer (MTP-32 microplate reader, Corona
Electric, Japan).
Drug interaction analysis
Additive or synergistic interaction between asiatic
acid andCPT-11 was determined byusing isobologram
analysis as described in detail previously (37, 38). The
type of interaction between asiatic acid and CPT-11
was evaluated by comparing the cytotoxic effects ob-
tained after simultaneous or sequential exposures to
the drugs with the ones observed after exposure to
asiatic acid or CPT-11 alone. Interaction indices were
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calculated by the following equation : interaction index=
asiatic acid c/asitic acid e＋CPT-11 c/CPT-11 e, where
asiatic acid e and CPT-11 e are concentrations of asiatic
acid and CPT-11 that inhibit 50, 60, 70% of proliferation
when used alone, and asiatic acid c and CPT-11 c are
concentrations of asiatic acid andCPT-11 that produce
the same effect when used in combination. According
to this method, an interaction index of less than 1.0
indicates synergistic interaction between two drugs,
an interaction index of more than 1.0 indicates an-
tagonism, and an index of 1.0 indicates additive inter-
action.
RESULTS
Cytotoxicity of asiatic acid
The viability of HT-29 cells exposed to asiatic acid for
24 h decreased in a dose-dependent manner to 4.8%
of the control level at a dose of 60 µg/ml (Fig.1B). The
concentration of 50% inhibition was 37.0±1.32 µg/ml.
This result indicates that asiatic acid is cytotoxic to
HT-29 cells.
DNA fragmentation
DNA ladder formation was observed inHT-29 cells
after 24 h of incubation with asiatic acid at concentra-
tions of 30, 40, 50 and 60 µg/ml in a dose-dependent
manner (Fig.2A). It was observed in parallel with
growth inhibition. DNA ladder formation caused by
treatment with 50 µg/ml of asiatic acid for 24 h was




Early apoptotic cells appeared in a dose-dependent
manner after treatment with 12.5 and 25 µg/ml of asi-
atic acid for 24 h(10.3 and 33.0%, respectively) (Fig.3).
Late apoptotic cells accounted for 8.6 and 95.4% of total
cells after treatment with 25 and 50 µg/ml of asiatic
acid for 24 h, respectively.
Bcl-2 and Bcl-xL expression in HT-29 cells
To elucidate involvement of Bcl-2 andBcl-xL proteins
in the asiatic acid-induced apoptosis in HT-29 cells, the
levels of theseproteinswereanalyzedbyWesternblotting
(Fig.4). WhenHT-29 cells were exposed to 50µg/ml of
Fig 3．Flow cytometric analysis of apoptosis in HT-29 cells exposed to asiatic acid. Cells were treated with various
concentrations of asiatic acid for 24 h and then stained with annexin V-FITC and PI. Values in the quadrants
indicate percentages in the total cells.
Fig 2．DNA fragmentation in HT-29 cells treated with asiatic acid. (A) Cells (1×106)
were cultured in the absence or presence of 10-60 µg/ml of asiatic acid for 24 h. (B)
HT-29 cells were treated with 0.1-30 µM Z-Asp-Glu-Val-Asp-FMK before adding 50 µg/ml
of asiatic acid. DNA was then extracted from the cells and analyzed by 2% agarose gel
electrophoresis. M, DNA size markers (100-bp ladders).








asiatic acid for 6, 12 and 24 h, the levels of Bcl-2 and
Bcl-xL proteins decreased time-dependently. After 24 h,
the levels of Bcl-2 andBcl-xL proteins standardizedwith
the level of β-actin reached 0% and 26.3% compared
with those at 0 h. These results suggest that down-
regulation of the anti-apoptotic proteins Bcl-2 and Bcl-
xL may correlate with apoptosis in HT-29 cells.
Fig 4．Western blot analysis. The expression levels of Bcl-2
(A) and Bcl-xL(B) proteins in HT-29 cells after treatment with
50 µg/ml of asiatic acid were determined byWestern blot analy-
sis. Twenty µg of protein was loaded in each lane in 12% SDS-
polyacrylamide gel electrophoresis. The protein recognized by
each antibody is indicated on the side. β-actin was detected as
an internal standard.
Fig 5．Activation of caspase-3 in HT-29 cells treated with asiatic
acid. HT-29 cells (1×106) were incubated with 25, 50 and 100 µg/
ml of asiatic acid for 12 h. Values aremeans±SD.Barswith ＊are sig-
nificantly different from the 0 µg/ml treatment group at p<0.0001.
Fig 6．Effect of combinational treatment of asiatic acid and CPT-
11 on the growth of HT-29 cells. (A) The cells were treated with
asiatic acid and CPT-11 simultaneously. (B) The cells were treated
with asiatic acid for 24 h and then with CPT-11 for a further 24 h.
(C) The cells were treated with CPT-11 for 24 h and then with
asiatic acid for a further 24 h. Concentrations ofCPT-11were 0 µM
(open box), 20 µM (hatched box), 40 µM (crossed box), 80 µM
(latticed box), 100 µM(dotted box) and 150 µM(closed box). Cyto-
toxicity was evaluated using the MTS assay. Data are expressed
as means±SD of three independent experiments.
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Activation of caspase-3 in HT-29 cells
To investigate the activation of caspase-3 during apop-
tosis, activity of caspase-3 wasmeasured by fluorometric
analysis using Ac-DEVD-AMC, a caspase-3-specific syn-
thetic substrate. Fig.5 shows significant activation of
caspase-3 in a dose-dependent manner in HT-29 cells
(p＜0.0001). Caspase-3 activity had increased to 6.3 fold
and 7.1 fold of the solvent control (P＜0.0001) at 12 h
after asiatic acid treatment at concentrations of 50 and
100 µg/ml, respectively.
Cytotoxicity of the asiatic acid/CPT-11combination
CPT-11 alone inhibited the growth of HT-29 cells in
a dose-dependent manner (Fig.6). Asiatic acid alone
also inhibited the growth of HT-29 cells in a dose-
dependent manner (Fig.6). Since asiatic acid and CPT-
11 showed cytotoxicity after 24 h at the concentrations
of 10 to 50 µg/ml (Fig.1) and 20 to 150 µM (Fig.6), re-
spectively, combinational treatment was done at these
concentrations for 24 h. When the cells were treated
simultaneously with asiatic acid and CPT-11, inter-
action indices at 50, 60 and 70% inhibition of prolif-
eration were 0.98±0.17, 0.92±0.08 and 0.93±0.09,
respectively, indicating an additive effect (Fig.6A).
When cells were first exposed to asiatic acid and then
treated with CPT-11, interaction indices were 0.99±
0.10, 0.93±0.15 and 0.88±0.17, respectively, indicating
an additive effect (Fig.6B). When cells were sequen-
tially exposed to CPT-11 and then asiatic acid, inter-
action indices at 50, 60 and 70% inhibition of prolifera-
tion were 0.87±0.08, 0.81±0.05 and 0.76±0.03 (Fig.6
C). A weak synergism was observed in this treatment.
DISCUSSION
Asiatic acid is an active principle inC. asiatica. Crude
extracts of this medicinal plant have shown chemo-
preventive effects in in vivo tumor models (1, 2). In an
in vitro experiment, asiatic acid induced apoptosis in
HepG2 human hepatoma cells (9). In this study, we
examined asiatic acid-induced apoptosis in human
colon tumor-derived cells, HT-29 cells. Asiatic acid dose-
dependently showed cytotoxicity in HT-29 cells (Fig.
1B). After asiatic acid treatment, DNA ladder formation
was observed (Fig.2A) and flow cytometric analysis
showed that annexin-positive cells increased dose-
dependently (Fig.3). Caspase-3, one of the effector pro-
teases in an apoptosis process (41), was activated by
asiatic acid (Fig.5). In the presence of the caspase-3
inhibitor Z-Asp-Glu-Val-Asp-FMK, DNA fragmenta-
tion triggered by asiatic acid was inhibited (Fig.2B).
These results indicate that asiatic acid inducedapoptosis
through activation of caspase-3, which cleaves DNA
fragmentation factor 45 (DFF45) in the DFF45/DFF
40 complex (42) and produces activeDFF40 to trigger
chromosomal DNA fragmentation.
Bcl-2 is an antiapoptotic protein, predominantly pre-
sent in the outer mitochondrial membrane, the endo-
plasmic reticulum membrane and the nuclear mem-
brane(13). Bcl-2 has been shown to inhibit cytochrome
c release frommitochondria into the cytosol by inhib-
iting insertion of the proapoptotic protein Bax in the
mitochondria or by directly or indirectly inhibiting Bax-
channel activity (13). Bcl-xL is also an antiapoptotic pro-
tein present in the cytosol, and it works to close the
channel (13, 43). Many tumor cells overexpress these
antiapoptotic proteins and become resistant to che-
motherapy and radiotherapy (14,15). Ohmori et al. (44)
reported that bcl-2 can modulate the cytotoxicity of
some anti-cancer agents such as CPT-11 andmitomycin
C by inhibiting the process of apoptosis. In the present
study, the levels of Bcl-2 and Bcl-xL were decreased
by treatment with asiatic acid, suggesting that down-
regulation of Bcl-2 and Bcl-xL in response to asiatic
acid may cause apoptosis. Since HT-29 cells carry high
levels of non-functional p53(45), asiatic acid-induced
apoptosis in these cells may not bemediated by activa-
tion of p53 but triggered by decrease in levels of Bcl-2
and Bcl-xL after asiatic acid treatment.
Systemic chemotherapy of colorectal cancer using
new agents that target specific molecular processes
of cell proliferation, vascularization, metastasis and
apoptosis inhibition have been developed (32). CPT-11
is a topoisomerase I inhibitor (18) and has been clini-
cally applied for treatment of patients with colorectal
cancer that is refractory to treatment with fluorouracil
(26, 27). Sensitivity of tumor cells to a topoisomerase in-
hibitor depends on topoisomerase I activity (19), tumor-
associated deficiency of p53(46), and the easiness of
apoptosis induction (47, 48). Combinationwith apotosis-
inducing agents would enhance the chemotherapeutic
response of colorectal cancer treated with topoisom-
erase I inhibitors. In this study, we examined effects
of combinational treatment with CPT-11 and asiatic
acid on cytotoxicity for HT-29 cells according to three
kinds of protocol : 1)simultaneous treatment, 2)first
exposed to asiatic acid and then treatedwithCPT-11, 3)
first exposed to CPT-11 and then treated with asiatic
acid. Simultaneous treatment and sequential treatment
in which cells were first treated with asiatic acid and
then with CPT-11 showed an additive cytotoxic effect.
Since asiatic acid is a derivative of ursolic acid, which
has been reported to block cell cycle progression in the
P. Bunpo et al. Effect of asiatic acid and CPT-11 on HT-29 cells７０
G1 phase (49), it is possible that a part of the HT-29
cell population treated with asiatic acid is blocked in
G1 phase and can no longer respond to CPT-11. The
remaining part of the cell population might enter S
phase and respond to CPT-11. On the other hand, syn-
ergism was observed when cells were first exposed
to CPT-11 and then treated with asiatic acid. In CPT-
11-pretreated cells, asiatic acid-mediated decrease in
the antiapoptotic proteins Bcl-2 and Bcl-xLmight en-
hance the apoptotic process, resulting in synergistic
cytotoxicity. Hayward et al. (48) reported that antisense-
mediated Bcl-xL knockdown enhances the response
to topoisomerase I inhibition in the colorectal cancer
cell line HCT 116. Although cytotoxic intensity of the
combinational treatment was dependent on the order
of the treatment, asiatic acid could possibly be used
to enhance the tumor cell-killing effect of the anticancer
drug CPT-11.
Combinational treatment with CPT-11 and asiatic
acid revealed additive or synergistic cytotoxicity in
HT-29 cells. The total triterpenic fraction of C. asiatica,
in which asiatic acid is one of main constituents, has
been used for treatment of venous hypertension in
clinical studies at a dose of 30 or 60 mg/day for 10
weeks or 4 months (50, 51). Taken together, the results
of this study suggest that asiatic acid enhances the
sensitivity of a tumor to anticancer drugs and reduces
the adverse effects of chemotherapy. The mechanism
of asiatic acid-induced apoptosis in colon cancer cells
should be clarified for introducing this compound to
clinical use.
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